retatrutide phase 2 trial results weight loss side effects cardiac 💉𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲'𝘀 𝗨𝗻𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁: 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂 𝗦𝗵𝗼𝘂𝗹𝗱 𝗞𝗻𝗼𝘄 𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲: a new triple-agonist Lilly's retatrutide shows 28% weight

(11) Chavez, A

The impact we are seeing in OA might be real, but we have to define it more clearly. Although no data are conclusive yet, preclinical studies have shown that GLP-1 receptor agonists can inhibit the NF-kB pathway, a key pathway involved in inflammation and cartilage destruction, according to Lane

(2021) 321:L991l1005

As of July 2026, Humana Medicare Advantage members with Part D coverage may also access GLP-1 weight loss medications through the new Medicare GLP-1 Bridge program at a flat $50 monthly copayment

If you are trying to decide whether a prescription program makes sense for you, the next practical step is to complete the free assessment quiz